Skip to Main Content

Aurinia Pharmaceuticals (AUPH) said Wednesday evening that an experimental medicine used to treat patients with lupus nephritis, an autoimmune kidney disease, achieved all primary and secondary efficacy goals in a late-stage clinical trial.

The drugmaker, headquartered near Vancouver, Canada, expects to submit a marketing application to the U.S. Food and Drug Administration in the first half of next year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!